Regulus Therapeutics reported $-6569000 in EBIT for its first fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Ebit Change
Alnylam Pharmaceuticals ALNY:US $ -191686000 44.95M
AstraZeneca AZN:LN 2.2B 673M
Astrazeneca AZN:US 2.2B 673M
Biogen BIIB:US $ 940.9M 409.4M
Celldex Therapeutics CLDX:US $ -21396000 1.86M
Gilead Sciences GILD:US $ 2029M 868M
GlaxoSmithKline GSK:LN 1.82B 600M
Intercept Pharmaceuticals ICPT:US $ -13363000 3.09M
Lexicon Pharmaceuticals LXRX:US -24007000 627K
Merk MRK:US $ 5711M 652M
Sangamo Biosciences SGMO:US $ -45734000 473K
Spectrum Pharmaceuticals SPPI:US $ -25392000 11.33M
Takeda 4502:JP 150.52B 152.13B
Vital Therapies VTL:US $ -20610000 825K
YTE INCY:US $ 260.29M 132.62M